Two healthcare stocks in the white-hot weight-loss segment tanked on Monday as one of their rivals zoomed higher. The ...

Conagra adds an ‘On Track’ badge on packaging for 26 of its Healthy Choice frozen meals that call out GLP-1 ...

The spot “is a clear violation” of the FDCA, “which requires that advertising for prescription drugs — including compounded ...

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

Innogen, a Shanghai-based medical technology company, announced that its independently developed, human-derived, ...

Given the number of comorbidities associated with obesity, the market's growth will impact the entire cardiometabolic disease ...

Novo Nordisk boasts 45 million customers using their drug Ozempic, which has caused a revolution in weight-loss treatment.

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of diabetes and obesity, while also delivering other health benefits, such as ...

What will it take for a clinical-stage biotech to break into the cardio space? One CEO thinks he has the answer.

The luster is starting to wear off GLP-1 weight-loss drugs including Wegovy and Ozempic as more clinicians warn patients ...

Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be a short-lived ...